Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females?
- PMID: 8740789
- DOI: 10.1093/oxfordjournals.annonc.a010569
Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females?
Abstract
Background: The treatment of Hodgkin's disease (HD) involves irradiation and chemotherapy. Both modalities may cause heart and lung injury. We aimed to assess 1) the occurrence of such injury, 2) the extent to which combined versus single-organ-affection resulted in disability, and 3) whether determinants for cardiopulmonary injury could be identified.
Patients and methods: A national cohort (n = 116) of HD patients (mean age 37 +/- 7 (SD) years, 67 males) was examined by interview, echocardiography, bicycle exercise test and lung function tests, 5-13 years after mediastinal irradiation with or without chemotherapy.
Results: Cardiac, pulmonary or combined sequelae occurred, respectively, in 21%, 15% and 19% of the patients affecting 75% of the females versus 41% of the males (P < 0.001). Of the patients with combined sequelae, 27% were disabled versus 4% of the rest (P < 0.05). Combined sequelae was associated with dyspnoea (P < 0.001) and reduced maximal exercise heart rate (P < 0.05). Compared to males, females had an increased risk of heart valve regurgitation (46% versus 16%, P < 0.001), pericardial thickening (22% versus 10%, P = 0.07) and reduced gas transfer (41% versus 22%, P = 0.03). Female gender was a significant risk factor for cardiac and/or pulmonary sequelae (OR 6.1, 95% CI 2.4-15.7), whereas age, follow-up period, smoking habits, histology, bulky mediastinal disease, radiation dose and chemotherapy were not. Mean exercise work capacity and O2-saturation were within normal limits.
Conclusions: Although cardiac and/or pulmonary sequelae were detected in more than half of the patients, only combined injury was associated with disability, dyspnoea and reduced performance. Females had an increased risk of cardiopulmonary sequelae, which could not be explained by treatment-related differences between the genders.
Similar articles
-
[Late complications after treatment of Hodgkin's disease].Tidsskr Nor Laegeforen. 1999 Mar 10;119(7):933-7. Tidsskr Nor Laegeforen. 1999. PMID: 10210953 Norwegian.
-
Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease.Ann Oncol. 1997;8 Suppl 1:19-24. Ann Oncol. 1997. PMID: 9187424
-
The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group.Ann Oncol. 1996;7 Suppl 4:67-72. doi: 10.1093/annonc/7.suppl_4.s67. Ann Oncol. 1996. PMID: 8836413 Review.
-
Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study.Heart. 1996 Jun;75(6):591-5. doi: 10.1136/hrt.75.6.591. Heart. 1996. PMID: 8697163 Free PMC article.
-
Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease.Ann Oncol. 1992 Sep;3 Suppl 4:111-5. doi: 10.1093/annonc/3.suppl_4.s111. Ann Oncol. 1992. PMID: 1450071 Review.
Cited by
-
[Carmustine Pulmonary Toxicity: A Diagnosis to Bear in Mind Even in Times of COVID].Arch Bronconeumol. 2021 Apr;57:52-54. doi: 10.1016/j.arbres.2021.01.009. Epub 2021 Feb 3. Arch Bronconeumol. 2021. PMID: 34629651 Free PMC article. Spanish. No abstract available.
-
Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.Bone Marrow Transplant. 2017 Apr;52(4):646-649. doi: 10.1038/bmt.2016.338. Epub 2016 Dec 19. Bone Marrow Transplant. 2017. PMID: 27991891 No abstract available.
-
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation.Br J Cancer. 2016 Jul 12;115(2):178-87. doi: 10.1038/bjc.2016.180. Epub 2016 Jun 28. Br J Cancer. 2016. PMID: 27351215 Free PMC article.
-
Common genetic variants of surfactant protein-D (SP-D) are associated with type 2 diabetes.PLoS One. 2013;8(4):e60468. doi: 10.1371/journal.pone.0060468. Epub 2013 Apr 5. PLoS One. 2013. PMID: 23577114 Free PMC article.
-
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.Am J Physiol Lung Cell Mol Physiol. 2011 Feb;300(2):L225-31. doi: 10.1152/ajplung.00264.2010. Epub 2010 Nov 19. Am J Physiol Lung Cell Mol Physiol. 2011. PMID: 21097524 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical